SG11201900776TA - Method of preventing or treating hearing loss - Google Patents
Method of preventing or treating hearing lossInfo
- Publication number
- SG11201900776TA SG11201900776TA SG11201900776TA SG11201900776TA SG11201900776TA SG 11201900776T A SG11201900776T A SG 11201900776TA SG 11201900776T A SG11201900776T A SG 11201900776TA SG 11201900776T A SG11201900776T A SG 11201900776TA SG 11201900776T A SG11201900776T A SG 11201900776TA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- preventing
- pct
- hearing loss
- treating hearing
- Prior art date
Links
- 206010011878 Deafness Diseases 0.000 title abstract 3
- 230000010370 hearing loss Effects 0.000 title abstract 3
- 231100000888 hearing loss Toxicity 0.000 title abstract 3
- 208000016354 hearing loss disease Diseases 0.000 title abstract 3
- 210000002768 hair cell Anatomy 0.000 abstract 2
- 230000030833 cell death Effects 0.000 abstract 1
- 230000007850 degeneration Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0046—Ear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 22 February 2018 (22.02.2018) WIP0 I PCT Hu omits I iolo 1111 1011 01100 1111 00 MOH ME (10) International Publication Number WO 2018/033543 Al (51) International Patent Classification: A61K 31/4439 (2006.01) A61P 27/16 (2006.01) A61K 31/519 (2006.01) (21) International Application Number: PCT/EP2017/070683 (22) International Filing Date: 15 August 2017 (15.08.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 16184541.7 17 August 2016 (17.08.2016) EP (71) Applicant: SUPPORT-VENTURE GMBH [CH/CH]; c/o Hoffmann & Co AG Lautengartenstr. 14, 4052 Basel (CH). (72) Inventor: BAUSCH, Alexander; Stettenweg 16, 4125 Riehen (CH). (74) Agent: SCHOLLHORN, Andreas; Latscha Schollhorn Partner AG, Austrasse 24, 4051 Basel (CH). = (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.1700) Published: with international search report (Art. 21(3)) 71' O 1-1 (54) Title: METHOD OF PREVENTING OR TREATING HEARING LOSS \" (57) : The present invention relates to methods of preventing or treating hearing loss and methods of preventing or inhibiting 0 hair cell degeneration or hair cell death in a subject.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16184541 | 2016-08-17 | ||
| PCT/EP2017/070683 WO2018033543A1 (en) | 2016-08-17 | 2017-08-15 | Method of preventing or treating hearing loss |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201900776TA true SG11201900776TA (en) | 2019-03-28 |
Family
ID=56740115
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201900776TA SG11201900776TA (en) | 2016-08-17 | 2017-08-15 | Method of preventing or treating hearing loss |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20190209568A1 (en) |
| EP (1) | EP3500258A1 (en) |
| JP (1) | JP2019528273A (en) |
| KR (1) | KR20190039142A (en) |
| CN (1) | CN109562105A (en) |
| AU (1) | AU2017313296A1 (en) |
| BR (1) | BR112019003006A2 (en) |
| CA (1) | CA3033887A1 (en) |
| CL (1) | CL2019000410A1 (en) |
| CO (1) | CO2019001402A2 (en) |
| EA (1) | EA201990220A1 (en) |
| IL (1) | IL264625A (en) |
| MA (1) | MA45981A (en) |
| MX (1) | MX2019001819A (en) |
| PE (1) | PE20190421A1 (en) |
| PH (1) | PH12019550015A1 (en) |
| SG (1) | SG11201900776TA (en) |
| WO (1) | WO2018033543A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021524493A (en) * | 2018-07-13 | 2021-09-13 | キナラス アーゲー | Combination of PPAR agonist and p38 kinase inhibitor for the prevention or treatment of fibrotic disease |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR240698A1 (en) | 1985-01-19 | 1990-09-28 | Takeda Chemical Industries Ltd | Process for the preparation of 5-(4-(2-(5-ethyl-2-pyridil)-ethoxy)benzyl)-2,4-thiazolodinedione and their salts |
| US5421818A (en) | 1993-10-18 | 1995-06-06 | Inner Ear Medical Delivery Systems, Inc. | Multi-functional inner ear treatment and diagnostic system |
| TWI249401B (en) * | 1999-04-14 | 2006-02-21 | Takeda Chemical Industries Ltd | Agent for improving ketosis |
| US20020151491A1 (en) * | 2000-11-28 | 2002-10-17 | Jian-Dong Li | Composition and method for treating the over-production of mucin in diseases such as otitis media using an inhibitor of MUC5AC |
| JP4064818B2 (en) | 2001-02-12 | 2008-03-19 | エフ．ホフマン−ラ ロシュ アーゲー | 6-substituted pyrido-pyrimidines |
| RU2348632C2 (en) | 2003-11-13 | 2009-03-10 | Ф.Хоффманн-Ля Рош Аг | Hydroxyalkyl-substituted pyrido-7-pyrimidine-7ons |
| WO2005115527A2 (en) | 2004-05-24 | 2005-12-08 | Auris Medical, Llc. | Combined otic aspirator and medication dispenser |
| CN101679211A (en) | 2007-06-15 | 2010-03-24 | 霍夫曼-拉罗奇有限公司 | A new method for the preparation of 3-amino-pentan-1,5-diol |
| CN107205995A (en) * | 2015-02-11 | 2017-09-26 | 投资支持有限公司 | Prevention or the method for the treatment of hearing loss |
| AU2017277478B2 (en) * | 2016-06-08 | 2023-03-16 | Support-Venture Gmbh | Pharmaceutical combinations for treating cancer |
-
2017
- 2017-08-15 SG SG11201900776TA patent/SG11201900776TA/en unknown
- 2017-08-15 KR KR1020197004579A patent/KR20190039142A/en not_active Ceased
- 2017-08-15 AU AU2017313296A patent/AU2017313296A1/en not_active Abandoned
- 2017-08-15 EA EA201990220A patent/EA201990220A1/en unknown
- 2017-08-15 MX MX2019001819A patent/MX2019001819A/en unknown
- 2017-08-15 CA CA3033887A patent/CA3033887A1/en not_active Abandoned
- 2017-08-15 WO PCT/EP2017/070683 patent/WO2018033543A1/en not_active Ceased
- 2017-08-15 MA MA045981A patent/MA45981A/en unknown
- 2017-08-15 EP EP17757503.2A patent/EP3500258A1/en not_active Withdrawn
- 2017-08-15 PE PE2019000369A patent/PE20190421A1/en unknown
- 2017-08-15 JP JP2019508866A patent/JP2019528273A/en not_active Withdrawn
- 2017-08-15 US US16/325,686 patent/US20190209568A1/en not_active Abandoned
- 2017-08-15 BR BR112019003006-9A patent/BR112019003006A2/en not_active IP Right Cessation
- 2017-08-15 CN CN201780049505.9A patent/CN109562105A/en active Pending
-
2019
- 2019-01-28 PH PH12019550015A patent/PH12019550015A1/en unknown
- 2019-02-03 IL IL264625A patent/IL264625A/en unknown
- 2019-02-14 CL CL2019000410A patent/CL2019000410A1/en unknown
- 2019-02-15 CO CONC2019/0001402A patent/CO2019001402A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20190209568A1 (en) | 2019-07-11 |
| IL264625A (en) | 2019-02-28 |
| WO2018033543A1 (en) | 2018-02-22 |
| EA201990220A1 (en) | 2019-08-30 |
| PH12019550015A1 (en) | 2019-07-24 |
| PE20190421A1 (en) | 2019-03-19 |
| CO2019001402A2 (en) | 2019-02-19 |
| MX2019001819A (en) | 2019-06-13 |
| CL2019000410A1 (en) | 2019-06-28 |
| JP2019528273A (en) | 2019-10-10 |
| AU2017313296A1 (en) | 2019-02-14 |
| KR20190039142A (en) | 2019-04-10 |
| BR112019003006A2 (en) | 2019-05-14 |
| CA3033887A1 (en) | 2018-02-22 |
| EP3500258A1 (en) | 2019-06-26 |
| CN109562105A (en) | 2019-04-02 |
| MA45981A (en) | 2019-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201900480YA (en) | Anti-tim-3 antibodies | |
| SG11201908567UA (en) | Modified cyclic dinucleotide compounds | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201908813QA (en) | Anti-sirp alpha antibodies | |
| SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201906431UA (en) | Method for the treatment of thromboembolism | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201907604UA (en) | Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan | |
| SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
| SG11201907023UA (en) | Method of reducing neutropenia | |
| SG11201902531QA (en) | Liquid pharmaceutical composition | |
| SG11201907196YA (en) | Composition and methods for preventing radiation injury and promoting tissue regeneration | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
| SG11201808566WA (en) | Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
| SG11201909825VA (en) | Hsp90 inhibitor oral formulations and related methods | |
| SG11201803643TA (en) | Virulence attenuated bacteria for treatment of malignant solid tumors |